Lapatinib and Capecitabine for Metastatic Breast Cancer
Author Information
Author(s): Sherrill B, Amonkar M M, Stein S, Walker M, Geyer C, Cameron D
Primary Institution: RTI Health Solutions
Hypothesis
Does the combination of lapatinib and capecitabine provide better quality-adjusted survival than capecitabine alone in women with HER2+ metastatic breast cancer?
Conclusion
The combination of lapatinib and capecitabine significantly improves quality-adjusted survival compared to capecitabine alone.
Supporting Evidence
- The combination therapy resulted in a 7-week difference in quality-adjusted survival.
- Patients on combination therapy experienced more time without severe toxicities.
- Quality-adjusted survival was significantly better for the combination group across various utility weightings.
Takeaway
Women with advanced breast cancer who took lapatinib with capecitabine lived better and longer than those who took capecitabine alone.
Methodology
A Q-TWiST analysis was conducted comparing the quality-adjusted survival of patients receiving lapatinib plus capecitabine versus capecitabine alone.
Potential Biases
Potential biases due to early study closure and crossover of patients to combination therapy.
Limitations
The study was stopped early, and the results may not reflect the full benefits of the treatment.
Participant Demographics
All participants had HER2+ metastatic breast cancer and had previously received standard therapies.
Statistical Information
P-Value
0.0013
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website